Ovarian hyperstimulation syndrome

Bailliere's Best Practice and Research in Clinical Obstetrics and Gynaecology

Volumn 14, Issue 1, 2000, Pages 103-122

  McElhinney, Bernie ^a   McClure, Neil ^a  

^a Institute of Clinical Sciences B   (United Kingdom)

Author keywords

Capillary permeability; Exaggerated folliculogenesis; Inflammatory cytokines; Ovarian hyperstimulation syndrome; Ovulation induction; Supportive management

Indexed keywords

ALBUMIN; ANGIOGENIC FACTOR; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTRADIOL; GROWTH FACTOR; IMMUNOGLOBULIN;

ANGIOGENESIS; ASCITES; CAPILLARY PERMEABILITY; ESTRADIOL BLOOD LEVEL; FEMALE; FLUID BALANCE; HUMAN; HYDROTHORAX; INFERTILITY THERAPY; KIDNEY FAILURE; KIDNEY PERFUSION; OVARY HYPERSTIMULATION; PERICARDIAL EFFUSION; PRIORITY JOURNAL; RESPIRATORY DISTRESS; REVIEW; THROMBOEMBOLISM; ULTRASOUND;

EID: 0034062822     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1053/beog.1999.0066     Document Type: Article

References (112)

1. Rabau E, Serr D M, David A. Human menopausal gonadotrophins for anovlation and sterility. American Journal of Obstetrics and Gynecology. 96:1967;92-98.
2. Schenker J G, Weinstein D. Ovarian hyperstimulation syndrome: a current survey. Fertility and Sterility. 30:1978;255-268.
3. Golan A, Ron-El R, Herman A. Ovarian hyperstimulation syndrome: an update review. Obstetrical and Gynaecological Survey. 44:1989;430-440.
4. Navot D, Bergh P A, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertility and Sterility. 58:1992;249-261.
5. Simon A, Revel A, Hurwitz A. The pathogenesis of ovarian hyperstimulation syndrome. Journal of Assisted Reproduction and Genetics. 15:1998;202-209.
6. MacDougall M J, Tan S L, Jacobs H S. In-vitro fertilization and the ovarian hyperstimulation syndrome. Human Reproduction. 7:1992;597-600.
7. Rizk B, Smitz J. Ovarian hyperstimulation syndrome after superovulation for IVF and related procedures. Human Reproduction. 7:1992;320-327.
8. Asch R H, Li H-P, Balmaceda J P. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Human Reproduction. 6:1991;1395-1399.
9. Delvigne A, Vandromme J, Barlow P. Are there predictive criteria of complicated ovarian hyperstimulation in IVF? Human Reproduction. 6:1991;959-962.
10. Haning R V, Austin C W, Carlson I H. Plasma estradiol is superior to ultrasound and urinary estriol glucuronide as a predictor of ovarian hyperstimulation syndrome during induction of ovulation with menotrophins. Fertility and Sterility. 40:1983;31-36.
11. Tulandi T, Meinnes R A, Arronet G H. Ovarian hyperstimulation syndrome following ovulation induction with hMG. International Journal of Fertility. 299:1984;113-117.
12. McClure N, Leya J, Radwanska E. Luteal phase support and ovarian hyperstimulation syndrome. Human Reproduction. 7:1992;758-764.
13. Yarali H, Fleige-Zahradka B G, Ho Yuen B, McComb F. The ascites in the ovarian hyperstimulation syndrome does not originate from the ovary. Fertility and Sterility. 59:1993;657-661.
14. Polishuk W, Schenker J. Ovarian hyperstimulation syndrome. Fertility and Sterility. 20:1969;433-450.
15. Tsirigotis M, Craft I. Ovarian hyperstimulation syndrome (OHSS): how much do we really know about it? European Journal of Obstetrics and Gynaecology. 55:1994;151-155.
16. Goldsman M, Pedram A, Dominguez C. Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertility and Sterility. 63:1995;268-272.
17. Yuen B H, McComb P, Sy L. Plasma prolactin, human chorionic gonadotrophin, estradiol, testosterone, and progesterone in the ovarian hyperstimulation syndrome. American Journal of Obstetrics and Gynecology. 133:1979;316-320.
18. Pride S, Yuen B, Moon Y. Clinical, endocrinological and intraovarian prostaglandin-F response to H-1 receptor blockade in the ovarian hyperstimulation syndrome. American Journal of Obstetrics and Gynecology. 148:1984;670-674.
19. Leung P, Yuen B, Moon Y. Effect of prolactin in an experimental model of the ovarian hyperstimulation syndrome. American Journal of Obstetrics and Gynecology. 145:1983;847-849.
20. Zaidise I, Friedman M, Lindenbaum E S. Serotonin and the ovarian hyperstimulation syndrome. European Journal of Obstetrics, Gynaecology, and Reproductive Biology. 15:1983;55-60.
21. Schenker J, Polishuk W. The role of prostaglandins in ovarian hyperstimulation syndrome. European Journal of Obstetrics, Gynaecology, and Reproductive Biology. 6:1976;742-744.
22. Orvieto R, Ben-Rafael Z. The immune system in severe ovarian hyperstimulation syndrome. Israel Journal of Medical Science. 32:1996;1180-1182.
23. Navot D, Margalioth E, Laufer N. Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertility and Sterility. 48:1987;57-61.
24. McClure N, Healy D, Rogers P. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet. 344:1994;235-236.
25. Ben-Rafael Z, Orvieto R. Cytokines - involvement in reproduction. Fertility and Sterility. 58:1992;1093-1099.
26. Adashi E Y. The potential relevance of cytokines to ovarian physiology: the emerging role of resident ovarian cells of the white blood cell series. Endocrine Reviews. 11:1990;454-464.
27. Espey L. Ovulation: an inflammatory reaction hypothesis. Biology of Reproduction. 22:1980;73-106.
28. Abramov Y, Schenker J G, Lewin A. Plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndrome. Human Reproduction. 11:1996;1381-1386.
29. Revel A, Barak V, Lavy W. Characterisation of intraperitoneal cytokines and nitrites in women with severe ovarian hyperstimulation syndrome. Fertility and Sterility. 66:1996;66-71.
30. Orvieto R, Ben-Rafael Z. Ovarian hyperstimulation syndrome: a new insight into an old enigma. Journal of the Society of Gynaecological Investigation. 5:1998;110-113.
31. Friedlander M R, Loret de Mola J, Goldfarb J. Elevated levels of interleukin-6 in ascites and serum from women with ovarian hyperstimulation syndrome. Fertility and Sterility. 60:1998;826-833.
32. Loret de Mola J, Flores J, Baumgardner G. Elevated interleukin-6 levels in the ovarian hyperstimulation syndrome: ovarian immunohistochemical localisation of interleukin-6 signal. Obstetrics and Gynaecology. 87:1996;581-587.
33. Kishimoto T. The biology of interleukin-6. Blood. 74:1989;1-10.
34. Itskovitz J, Sealey J E, Glorioso N. Plasma prorenin response to human chorionic gonadotrophin in ovarian hyperstimulated women: correlation with the number of ovarian follicles and steroid hormone concentrations. Proceedings of the National Academy of Sciences of the USA. 84:1987;7285-7289.
35. Sealey J E, Itskovitz-Eldor J, Rubattu S. Estradiol- and progesterone-related increases in the renin-aldosterone system: studies during ovarian stimulation and early pregnancy. Journal of Clinical Endocrinology. 79:1994;258-264.
36. Oparil S, Ehrlich E N, Lindheimer M D. Effects of progesterone on renal sodium handling in man: relation to aldosterone excretion and plasma renin activity. Clinical Science and Molecular Medicine. 49:1975;139-147.
37. Glorioso N, Atlas S A, Laragh J H. Prorenin in high concentrations in human ovarian follicular fluid. Science. 233:1986;1422-1424.
38. Morris R S, Paulson R J. The ovarian renin-angiotensin system: recent advances and their relationships to assisted reproductive technologies. Assisted Reproductive Reviews. 3:1993;88-94.
39. Sealey J E, Glorioso N, Itskovitz J. Stimulation of plasma prorenin by gonadotrophic hormones. American Journal of Obstetrics and Gynecology. 153:1985;596-597.
40. Ong A CM, Eisen V, Rennie D P. The pathogenesis of the ovarian hyperstimulation syndrome (OHS): a possible role for ovarian renin. Clinical Endocrinology. 34:1991;43-49.
41. Thomas W, Sernia C. The immunocytochemical localization of angiotensinogen in the rat ovary. Cell Tissue Research. 261:1990;367-373.
42. Yoshimura Y, Karube M, Oda T. Locally produced angiotensin II induces ovulation by stimulating prostaglandin production in in vitro perfused rabbit ovaries. Endocrinology. 133:1993;1609-1616.
43. Fernandez C A, Twickler J, Mead A. Neovascularisation produced by angiotensin II. Journal of Laboratory and Clinical Medicine. 105:1985;141-145.
44. Robertson A L, Khairallah P A. Effects of angiotensin II and some analogues on vascular permeability in the rabbit. Journal of Laboratory and Clinical Medicine. 31:1972;923-931.
45. Delbaere A, Bergmann P JM, Gervy-Decoster C. Angiotensin 2 immunoreactivity is elevated in ascites during severe ovarian hyperstimulation syndrome: implications of pathophysiology and clinical management. Fertility and Sterility. 62:1994;731-737.
46. Balasch J, Arroyo V, Fabregues F. Neurohormonal and hemodynamic changes in severe cases of the ovarian hyperstimulation syndrome. Annals of Internal Medicine. 121:1994;27-33.
47. Balasch J, Fabregues F, Arroyo V. Peripheral arterial vasodilatation hypothesis: a new insight into the pathogenesis of ovarian hyperstimulation syndrome. Human Reproduction. 13:1998;2718-2730.
48. Haning R V Jr, Strawn E Y, Nolton W E. Pathophysiology of the ovarian hyperstimulation syndrome. Obstetrics and Gynaecology. 66:1985;220-224.
49. McClure N, Macpherson A M, Healy D L. An immunohistochemical study of the vascularization of the human Graaffian follicle. Human Reproduction. 9:1994;1401-1405.
50. Aboulghar M A, Mansour R T, Serour G I. Elevated concentrations of angiogenin in serum and ascitic fluid from patients with severe ovarian hyperstimulation syndrome. Human Reproduction. 13:1998;2068-2071.
51. Dvorak H, Brown L, Detmar M, Dvorak A. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. American Journal of Pathology. 146:1995;1029-1039.
52. Thomas K. Vascular endothelial growth factor, a potent and selective angiogenic agent. Journal of Biological Chemistry. 271:1996;603-606.
53. Kobayashi H, Okada Y, Asahina T. The kallikrein-kinin system, but not vascular endothelial growth factor, plays a role in the increased vascular permeability associated with ovarian hyperstimulation syndrome. Journal of Molecular Endocrinology. 20:1998;363-374.
54. Krasnow J, Berga S, Guzick D. Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: a preliminary report. Fertility and Sterility. 65:1996;552-555.
55. Abramov Y, Barak V, Nisman B, Schenker J. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertility and Sterility. 67:1997;261-265.
56. Risk B, Aboulghar M. Modern management of ovarian hyperstimulation syndrome. Human Reproduction. 6:1991;1082-1087.
57. Kodama H, Fukuda J, Karube H. Status of the coagulation and fibrinolytic systems in ovarian hyperstimulation syndrome. Fertility and Sterility. 66:1996;417-423.
58. Gao X, Greenbaum L M, Mahesh V B, Brann D W. Characterisation of the kinin system in the ovary during ovulation in the rat. Biological Reproduction. 47:1992;945-951.
59. Tei T, Ujioka T, Matsuura K. Possible role of kinin-kallikrein system in pathophysiology of ovarian hyperstimulation syndrome. Biology of Reproduction. 56:1997;469.
60. Dahl Lyons C, Wheeler C A, Frishman G N. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Human Reproduction. 9:1994;792-799.
61. Koninckx P, Renaer M, Brosens I. Origin of peritoneal fluid in women: an ovarian exudation product. British Journal of Obstetrics and Gynaecology. 87:1980;177-183.
62. Elchalal U, Schenker J. The pathophysiology of ovarian hyperstimulation syndrome - views and ideas. Human Reproduction. 12:1997;1129-1137.
63. Friedler S, Rachstein A, Bukovsky I. Unilateral hydrothorax as a sole and recurrent manifestation of ovarian hyperstimulation syndrome following in-vitro fertilization. Human Reproduction. 13:1998;859-861.
64. Wood N, Edozien L, Lieberman B. Symptomatic unilateral pleural effusion as a presentation of ovarian hyperstimulation syndrome. Human Reproduction. 13:1998;571-572.
65. Pintucci G, Lacoviello L, Castelli M P. Cathepsin G-induced released of PAI-1 in the culture medium of endothelial cells: a new thrombogenic role for polymorphonuclear monocytes leukocytes? Journal of Laboratory and Clinical Medicine. 122:1992;69-79.
66. Germond M, Wirthner D, Thorin D. Aorto-subclavian thromboembolism: a rare complication associated with moderate ovarian hyperstimulation syndrome. Human Reproduction. 11:1996;1173-1176.
67. Manaka T, Akahori A, Araki S, Tamada T. Changes in coagulation and fibrinolytic activity in patients with ovarian hyperstimulation syndrome. Nippon Sankal Fujinka Gakkai Zassi. 43:1991;1653-1659.
68. Brinsden P, Wada I, Tan S. Diagnosis, prevention and management of ovarian hyperstimulation syndrome. British Journal of Obstetrics and Gynaecology. 102:1995;767-772.
69. Zalel Y. Recurrent spontaneous ovarian hyperstimulation syndrome. American Journal of Obstetrics and Gynecology. 179:1998;835-836.
70. Akagbosu F, Marcus S, Abusheikha N. Does ovarian hyperstimulation syndrome affect the quality of oocytes? Human Reproduction. 13:1998;2583-2584.
71. Lunenfeld B, Serr D M, Mashiach S. Therapy with gonadotrophins: where are we today? Analysis of 2890 menotropin treatment cycles in 914 patients. Insler V, Bettendorf G. Advances in Diagnosis and Treatment of Infertility. 1981;27 Elsevier, Amsterdam.
72. Shoham Z, Zouves C, Insler V. Early miscarriage and fetal malformations after induction of ovulation (by clomiphene citrate and/or human menotrophins), in vitro fertilization, and gamete intrafallopian transfer. Fertility and Sterility. 55:1991;1-13.
73. Atlas M, Menczer J. Massive hyperstimulation and borderline carcinoma of the ovary. Acta Obstetrica et Gynecologica Scandinavica. 61:1982;261-263.
74. Tortoriello D, McGovern P, Colon J. 'Coasting' does not adversely affect cycle outcome in a subset of highly responsive in vitro fertilization patients. Fertility and Sterility. 69:1998;454-460.
75. Sher G, Zouves C, Feinman M, Maassarani G. Prolonged coasting: an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization. Human Reproduction. 10:1995;3107-3109.
76. Forman R, Frydman R, Egan D. Severe ovarian hyperstimulation syndrome using agonists of gonadotrophin-releasing hormone for in vitro fertilisation: a European series and a proposal for prevention. Fertility and Sterility. 53:1990;502-509.
77. Rabinowitz R, Laufer N, Lewin A. Rate of ovarian hyperstimulation syndrome after high dose HMG for the induction of ovulation in IVF cycles. Human Reproduction. 2:1987;48.
78. Araujo E, Bernardini L, Frederick J. Prospective randomized comparison of human chorionic gonadotrophin versus intramuscular progesterone for luteal-phase support in assisted reproduction. Journal of Assisted Reproduction and Genetics. 11:1994;74-78.
79. Golan A, Ron-El R, Herman A. Ovarian hyperstimulation following D-Trp-6 luteinizing hormone-releasing hormone microcapsules and menotropin for in vitro fertilization. Fertility and Sterility. 50:1988;912-916.
80. Claman P, Domingo M, Leader A. Luteal phase support in in-vitro fertilization using gonadotrophin releasing hormone analogue before ovarian stimulation: a prospective randomized study of human chorionic gonadotrophin versus intramuscular progesterone. Human Reproduction. 7:1992;487-489.
81. Wada I, Mayson P, Troup S. Does elective cryopreservation of all embryos from women at risk of ovarian hyperstimulation syndrome reduce the incidence of the condition. British Journal of Obstetrics and Gynaecology. 100:1993;265-269.
82. Benadiva C, Moomjy M, Davis O. Withholding gonadotrophin administration is an effective alternative for the prevention of ovarian hyperstimulation syndrome. Fertility and Sterility. 67:1997;724-727.
83. Bassil S, Godin P, Stallaert S. Ovarian hyperstimulation syndrome: a review. Assisted Reproduction Reviews. 5:1995;90-96.
84. Blankstein J, Shalev J, Saadon T. Ovarian hyperstimulation syndrome: prediction by number and size of preovulatory ovarian follicles. Fertility and Sterility. 47:1987;597-602.
85. Zalud I, Kurjak A. The assessment of luteal blood flow in pregnant and non-pregnant women by transvaginal and color doppler. Journal of Perinatal Medicine. 18:1990;215-221.
86. Moohan J, Curcio K, Leoni M. Low intraovarian vascular resistance: a marker for severe ovarian hyperstimulation syndrome. Fertility and Sterility. 67:1997;728-732.
87. Pride S, James C, Yuen B. The ovarian hyperstimulation syndrome. Seminars in Reproductive Endocrinology. 8:1990;247-260.
88. Meirow D, Schenker J, Rosler A. Ovarian hyperstimulation syndrome with low oestradiol in non-classical 17alpha-hydroxylase, 17,20-lyase deficiency: what is the role of oestrogens? Human Reproduction. 11:1996;2119-2121.
89. Navot D, Relou A, Birkenfeld A. Risk factors and prognostic variables in ovarian hyperstimulation syndrome. American Journal of Obstetrics and Gynecology. 159:1988;210-215.
90. Haning R, Austin C, Carlson I. Plasma estradiol is superior to ultrasound and urinary estriol glucuronide as a predictor of ovarian hyperstimulation syndrome during induction of ovulation with gonadotrophins. Fertility and Sterility. 40:1983;31-36.
91. Artini P, Fasciani A, Monti M. Changes in vascular endothelial growth factor levels and the risk of ovarian hyperstimulation syndrome in women enrolled in an in vitro fertilization program. Fertility and Sterility. 70:1998;560-564.
92. Orvieto R, Voliovitch I, Fishman P, Ben-Rafael Z. Interleukin-2 and ovarian hyperstimulation syndrome: a pilot study. Human Reproduction. 10:1995;24-27.
93. Brock T A, Dvorak H F, Senger D R. Tumour-secreted vascular-permeability factor increases cytosolic CA2+ and Von Willebrand factor release in human endothelial-cells. American Journal of Pathology. 138:1991;213-221.
94. Todorow S, Schricker S, Siebzehnruebl E. von Willebrand factor: an endothelial marker to monitor in-vitro fertilisation patients with ovarian hyperstimulation syndrome. Human Reproduction. 8:1993;2039-2046.
95. Abe Y, Horiuchi A, Miyake M, Kimura S. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunology Reviews. 139:1994;5-19.
96. Orvieto R, Achiron A, Margalit R, Ben-Rafael Z. The role of intravenous immunoglobulin in the prevention of severe ovarian hyperstimulation syndrome. Journal of Assisted Reproduction and Genetics. 14:1997;79S.
97. Asch R H, Ivery G, Goldsman M. The use of intravenous albumin in patients at risk for severe ovarian hyperstimulation syndrome. Human Reproduction. 8:1993;1015-1020.
98. Shoham Z, Weissman A, Barash A. Intravenous albumin for the prevent of severe ovarian hyperstimulation syndrome in an in vitro fertilisation program: a prospective, randomised placebo-controlled study. Fertility and Sterility. 62:1994;137-142.
99. Lewit N, Kol S, Ronen N, Itskovitz-Eldor J. Does intravenous administration of human albumin prevent severe ovarian hyperstimulation syndrome. Fertility and Sterility. 66:1996;654-656.
100. Ndukwe G, Thorton S, Fishel S. Severe ovarian hyperstimulation syndrome: is it really preventable by prophylactic intravenous albumin? Fertility and Sterility. 68:1997;851-854.
101. Morris R, Wong I, Kirkman E. Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome. Human Reproduction. 10:1995;1355-1358.
102. Tan S L, Balen A, Hussein E L. The use of glucocorticoids for the prevention of ovarian hyperstimulation syndrome in IVF. Fertility and Sterility. 58:1992;378-383.
103. Borenstein R, Elhalah U, Lunenfeld B, Schwartz Z. Severe ovarian hyperstimulation syndrome: a reevaluated therapeutic approach. Fertility and Sterility. 51:1989;791-795.
104. Ferraretti A P, Gianaroli L, Diotallevi L. Dopamine treatment for severe hyperstimulation syndrome. Human Reproduction. 7:1992;180-183.
105. Pride S, Yuen B, Moon Y, Leung P. Relationship of gonadotrophin-releasing hormone, danazol, and prostaglandin blockade to ovarian enlargement and ascites formation of the ovarian hyperstimulation syndrome in the rabbit. American Journal of Obstetrics and Gynecology. 154:1986;1155-1160.
106. Thaler I, Yoffe N, Kaftory J, Brandes J. Treatment of ovarian hyperstimulation syndrome: the physiological basis for a modified approach. Fertility and Sterility. 36:1981;110-113.
107. Knox G. Antihistamine blockade of the ovarian hyperstimulation syndrome. American Journal of Obstetrics and Gynecology. 118:1974;992-994.
108. Erlik Y, Naot Y, Friedman M. Histamine levels in ovarian hyperstimulation syndrome. Obstetrics and Gynecology. 53:1979;580-582.
109. Zaidise I, Lindenbaum E, Askenazi R. Serotonin and the ovarian hyperstimulation syndrome. European Journal of Obstetrics, Gynaecology, and Reproductive Biology. 15:1983;55-60.
110. Aboulghar M A, Mansour R T, Serour G I. Autotransfusion of the ascitic fluid in the treatment of severe ovarian hyperstimulation syndrome. Fertility and Sterility. 58:1992;1056-1059.
111. Hurwitz A, Milwidsky A, Yagel S, Adoni A. Early unwinding of torsion of an ovarian cyst as a result of hyperstimulation syndrome. Fertility and Sterility. 40:1983;393.
112. Ferrara J LM. Cytokine inhibitors and graft-versus-host disease. Annals of the New York Academy of Science. 770:1995;227-236.